Health
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE – PharmiWeb.com
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE…
ASTRAZENECA SECURES LICENSE EXTENSION AND EARLY NHS ENGLAND ACCESS TO TAGRISSOTM (osimertinib) FOR PATIENTS WITH COMPLETELY RESECTED EARLY-STAGE EGFR MUTATION-POSITIVE NON-SMALL CELL LUNG CANCER
- This is the first authorisation to be issued by the MHRA under Project Orbis.1
- AstraZeneca, NHS England and NICE have reached an agreement to enable early access to osimertinib for patients with this type of cancer, while NICE undertakes its appraisal.
- Patients with early-stage lung cancer are treated…
Continue Reading
-
Noosa News23 hours agoCommissioner thanks police officer who threw a speed radar at a car
-
Noosa News22 hours agoDefence investigation finds Taipan pilot’s actions possibly prevented further fatalities in crash
-
Noosa News21 hours agoNo matter what happens in his Origin debut, history beckons for rookie maroon Robert Toia
-
General19 hours agoDairy farmers devastated by floods across parts of New South Wales